Jeff Sessions is launching a crusade against the opioid crisis plaguing America.
- Why Jeff Sessions Can't Fix the Opioid Crisis on His Own
- Prediction: The Next Drug Price Gouge We See Will Be the Zika Vaccine
- Why Valeant Pharmaceuticals Stock Tanked 24% This Month (NYSE: VRX)
- Pharmaceutical Companies Hike Prescription Prices 76% Since 2010
We could see a Zika drug price gouge in the not so distant future - thanks to the French big pharma firm that is taking the medication's trials over from the U.S. Army.
But that's hardly the worst part of this potential big pharma/U.S. government drug transaction.
Valeant Pharmaceuticals Stock (NYSE: VRX) is up 5% today (Friday) to $178.49 as the pharmaceutical stock continues its week of extreme volatility.
But even with today's gain, VRX stock has dropped 24% in the last month.
Pharmaceutical companies have been raising the price of prescription drugs at an alarming rate since 2010.
According to a new report from The Wall Street Journal, the 30 highest-selling drugs in the United States saw their prices increase roughly 76% from 2010 through 2014.